Skip to main content
padlock icon - secure page this page is secure

American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short‐term possibilities for an alternative treatment

Buy Article:

$52.00 + tax (Refund Policy)

Meglumine antimoniate (MA; Glucantime®), the 80‐year‐old first‐line systemic treatment for all forms of American tegumentary leishmaniasis (ATL) caused by Leishmania (Viannia) braziliensis, Leishmania (Viannia) guyanensis and Leishmania (Leishmania) amazonensis, is highly toxic, presents adverse side‐effects and may not attain clinical and parasitological cure. This critical review examines the necessity for intramuscular/intravenous administration of MA, the alternatives to this approach, and the possibilities of developing affordable, accessible and non‐toxic drugs or new delivery methods.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: N‐méthyl glucamine; N–methyl glucamine; antimoine pentavalent; cutaneous leishmaniasis; drug repositioning; leishmaniose cutanée; nanomedicine; nanomédecine; pentavalent antimonial; repositionnement de médicament

Document Type: Research Article

Publication date: April 1, 2019

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more